Published in J Natl Cancer Inst on October 10, 2013
Associations of Oral α-, β-, and γ-Human Papillomavirus Types With Risk of Incident Head and Neck Cancer. JAMA Oncol (2016) 0.87
Diabetes and pancreatic cancer survival: a prospective cohort-based study. Br J Cancer (2014) 0.86
Laboratory detective work identifies a mishandling problem in sample aliquoting. Biopreserv Biobank (2014) 0.75
The Prostate, Lung, Colorectal and Ovarian Cancer (PLCO) Screening Trial Pathology Tissue Resource. Cancer Epidemiol Biomarkers Prev (2016) 0.75
Dietary Fat Intake and Lung Cancer Risk: A Pooled Analysis. J Clin Oncol (2017) 0.75
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
Prostate-cancer mortality at 11 years of follow-up. N Engl J Med (2012) 16.91
Screening for colorectal cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2008) 16.82
Screening for prostate cancer: U.S. Preventive Services Task Force recommendation statement. Ann Intern Med (2012) 15.83
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design of the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial. Control Clin Trials (2000) 10.99
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
The Nurses' Health Study: lifestyle and health among women. Nat Rev Cancer (2005) 8.19
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial of the National Cancer Institute: history, organization, and status. Control Clin Trials (2000) 6.17
Effect of a US National Institutes of Health programme of clinical trials on public health and costs. Lancet (2006) 3.56
An analysis of bibliometric indicators, National Institutes of Health funding, and faculty size at Association of American Medical Colleges medical schools, 1997-2007. J Med Libr Assoc (2008) 1.70
Overdetection, overtreatment and costs in prostate-specific antigen screening for prostate cancer. Br J Cancer (2009) 1.59
Screening for ovarian cancer: U.S. Preventive Services Task Force reaffirmation recommendation statement. Ann Intern Med (2012) 1.58
Criteria for the evaluation of large cohort studies: an application to the nurses' health study. J Natl Cancer Inst (2008) 1.06
Reduced lung-cancer mortality with low-dose computed tomographic screening. N Engl J Med (2011) 38.61
Mortality results from a randomized prostate-cancer screening trial. N Engl J Med (2009) 30.05
A genome-wide association study identifies alleles in FGFR2 associated with risk of sporadic postmenopausal breast cancer. Nat Genet (2007) 22.96
The decrease in breast-cancer incidence in 2003 in the United States. N Engl J Med (2007) 12.23
Prostate cancer screening in the randomized Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial: mortality results after 13 years of follow-up. J Natl Cancer Inst (2012) 11.91
Colorectal-cancer incidence and mortality with screening flexible sigmoidoscopy. N Engl J Med (2012) 11.48
Design and endpoints of clinical trials in hepatocellular carcinoma. J Natl Cancer Inst (2008) 11.27
Effect of screening on ovarian cancer mortality: the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Randomized Controlled Trial. JAMA (2011) 9.13
A multistage genome-wide association study in breast cancer identifies two new risk alleles at 1p11.2 and 14q24.1 (RAD51L1). Nat Genet (2009) 8.39
Newly discovered breast cancer susceptibility loci on 3p24 and 17q23.2. Nat Genet (2009) 7.30
Screening by chest radiograph and lung cancer mortality: the Prostate, Lung, Colorectal, and Ovarian (PLCO) randomized trial. JAMA (2011) 6.45
The National Lung Screening Trial: overview and study design. Radiology (2010) 6.43
Results of initial low-dose computed tomographic screening for lung cancer. N Engl J Med (2013) 5.92
Performance of common genetic variants in breast-cancer risk models. N Engl J Med (2010) 5.79
A common standard for conflict of interest disclosure in addiction journals. Addiction (2009) 5.62
Genome-wide association study identifies variants in the ABO locus associated with susceptibility to pancreatic cancer. Nat Genet (2009) 5.14
A genome-wide association study identifies pancreatic cancer susceptibility loci on chromosomes 13q22.1, 1q32.1 and 5p15.33. Nat Genet (2010) 4.89
Comorbidity and mortality results from a randomized prostate cancer screening trial. J Clin Oncol (2010) 4.84
Probability of cancer in pulmonary nodules detected on first screening CT. N Engl J Med (2013) 4.64
A multi-stage genome-wide association study of bladder cancer identifies multiple susceptibility loci. Nat Genet (2010) 3.93
New models for large prospective studies: is there a better way? Am J Epidemiol (2012) 3.85
Results of repeat sigmoidoscopy 3 years after a negative examination. JAMA (2003) 3.82
Genome-wide association studies identify four ER negative-specific breast cancer risk loci. Nat Genet (2013) 3.81
Cumulative incidence of false-positive test results in lung cancer screening: a randomized trial. Ann Intern Med (2010) 3.79
Selection criteria for lung-cancer screening. N Engl J Med (2013) 3.69
Detectable clonal mosaicism and its relationship to aging and cancer. Nat Genet (2012) 3.69
Circulating 25-hydroxyvitamin D and risk of pancreatic cancer: Cohort Consortium Vitamin D Pooling Project of Rarer Cancers. Am J Epidemiol (2010) 3.51
Prostate cancer screening in the Prostate, Lung, Colorectal and Ovarian cancer screening trial: update on findings from the initial four rounds of screening in a randomized trial. BJU Int (2008) 3.51
American society of clinical oncology clinical practice guideline update on the use of pharmacologic interventions including tamoxifen, raloxifene, and aromatase inhibition for breast cancer risk reduction. J Clin Oncol (2009) 3.51
A common variant at the TERT-CLPTM1L locus is associated with estrogen receptor-negative breast cancer. Nat Genet (2011) 3.37
Methods for etiologic and early marker investigations in the PLCO trial. Mutat Res (2005) 3.33
Utilization of surveillance colonoscopy in community practice. Gastroenterology (2009) 3.33
Ovarian cancer biomarker performance in prostate, lung, colorectal, and ovarian cancer screening trial specimens. Cancer Prev Res (Phila) (2011) 3.33
Ovarian cancer screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) cancer screening trial: findings from the initial screen of a randomized trial. Am J Obstet Gynecol (2005) 3.25
Race and colorectal cancer disparities: health-care utilization vs different cancer susceptibilities. J Natl Cancer Inst (2010) 3.16
Using relative utility curves to evaluate risk prediction. J R Stat Soc Ser A Stat Soc (2009) 3.04
Serum vitamin D concentration and prostate cancer risk: a nested case-control study. J Natl Cancer Inst (2008) 3.04
A framework for evaluating biomarkers for early detection: validation of biomarker panels for ovarian cancer. Cancer Prev Res (Phila) (2011) 3.03
Prostate biopsy following a positive screen in the prostate, lung, colorectal and ovarian cancer screening trial. J Urol (2005) 3.01
Genome-wide association study of renal cell carcinoma identifies two susceptibility loci on 2p21 and 11q13.3. Nat Genet (2010) 2.96
Prostate Cancer Screening in the Prostate, Lung, Colorectal and Ovarian (PLCO) Cancer Screening Trial: findings from the initial screening round of a randomized trial. J Natl Cancer Inst (2005) 2.82
Promoting healthy skepticism in the news: helping journalists get it right. J Natl Cancer Inst (2009) 2.82
Recent trends in incidence of cutaneous melanoma among US Caucasian young adults. J Invest Dermatol (2008) 2.80
Final results of the Lung Screening Study, a randomized feasibility study of spiral CT versus chest X-ray screening for lung cancer. Lung Cancer (2005) 2.79
Benefits and harms of computed tomography lung cancer screening strategies: a comparative modeling study for the U.S. Preventive Services Task Force. Ann Intern Med (2013) 2.77
Results of the two incidence screenings in the National Lung Screening Trial. N Engl J Med (2013) 2.66
Baseline characteristics of participants in the randomized national lung screening trial. J Natl Cancer Inst (2010) 2.50
A meta-analysis of genome-wide association studies of breast cancer identifies two novel susceptibility loci at 6q14 and 20q11. Hum Mol Genet (2012) 2.45
Assessing contamination and compliance in the prostate component of the Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial. Clin Trials (2010) 2.38
Genome-wide association study of follicular lymphoma identifies a risk locus at 6p21.32. Nat Genet (2010) 2.37
Lung cancer risk prediction: Prostate, Lung, Colorectal And Ovarian Cancer Screening Trial models and validation. J Natl Cancer Inst (2011) 2.31
Long-term variation in serum 25-hydroxyvitamin D concentration among participants in the Prostate, Lung, Colorectal, and Ovarian Cancer Screening Trial. Cancer Epidemiol Biomarkers Prev (2010) 2.28
Flexible sigmoidoscopy in the PLCO cancer screening trial: results from the baseline screening examination of a randomized trial. J Natl Cancer Inst (2005) 2.27